SCHEMBL962105

SCHEMBL962105

NC(=O)[C@@](c1ccccc1)(C1CCCCC1)C1CCNC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 5/20 0.45
▸ HRH1 P35367 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ SCN1A P35498 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ SCN2A Q99250 1/20 0.45
▸ SCN3A Q9NY46 1/20 0.45
▸ KEAP1 Q14145 1/20 0.44
▸ NFE2L2 Q16236 1/20 0.44
▸ KIF11 P52732 1/20 0.40
▸ CHRM2 P08172 6/20 0.39
▸ CHRM1 P11229 6/20 0.39
▸ CHRM3 P20309 6/20 0.39
▸ KCNH2 Q12809 3/20 0.37
▸ CHRM4 P08173 2/20 0.37
▸ CHRM5 P08912 2/20 0.37
▸ GRIN2D O15399 1/20 0.37
▸ GRIN3B O60391 1/20 0.37
▸ GRIN1 Q05586 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL962104 1.00 CYP2D6 (0.45) CYP2D6HRH1MEN1LMNASCN1A
SCHEMBL960975 0.99 KMT2A (0.46) CYP2D6HRH1MEN1LMNASCN1A
SCHEMBL960974 0.99 KMT2A (0.46) CYP2D6HRH1MEN1LMNASCN1A
SCHEMBL962721 0.96 KMT2A (0.46) CYP2D6HRH1MEN1LMNASCN1A
SCHEMBL962720 0.96 KMT2A (0.46) CYP2D6HRH1MEN1LMNASCN1A
SCHEMBL29116795 0.87 KEAP1 (0.56) CYP2D6HRH1KMT2AKEAP1NFE2L2
SCHEMBL5176133 0.82 MAPT (0.42) CYP2D6HRH1MEN1LMNASCN1A
SCHEMBL958241 0.80 KMT2A (0.50) CYP2D6HRH1MEN1LMNASCN1A
SCHEMBL953947 0.80 KMT2A (0.50) CYP2D6HRH1MEN1LMNASCN1A
SCHEMBL4396455 0.80 KMT2A (0.50) CYP2D6HRH1MEN1LMNASCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008278-B2 Diarylmethyl and related compounds THERAVANCE, INC. (US) 2011-08-30 — — US disclosed
US-20110015152-A1 DIARYLMETHYL AND RELATED COMPOUNDS THERAVANCE, INC. (US) 2011-01-20 — — US disclosed
US-7829728-B2 Diarymethyl and related compounds THERAVANCE, INC. (US) 2010-11-09 — — US disclosed
US-20080114030-A1 Diarymethyl and related compounds THERAVANCE BIOPHARMA R&D IP, LLC 2008-05-15 — — US disclosed
US-7317102-B2 Diarylmethyl and related compounds THERAVANCE, INC. (US) 2008-01-08 — — US disclosed
US-20060287369-A1 Diarylmethyl and related compounds THERAVANCE BIOPHARMA R&D IP, LLC 2006-12-21 — — US disclosed
EP-1615881-A2 DIARYLMETHYL AND RELATED COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY Theravance, Inc. (US) 2006-01-18 — — EP disclosed
WO-2004089892-A2 DIARYLMETHYL AND RELATED COMPOUNDS HAVING BETA2 ANDRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY THERAVANCE, INC. (US) 2004-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114030-A1 Diarymethyl and related compounds ADRB2, ADRB1, ADRA2B CYP2D6 554/4885HRH1 78/4885MEN1 3945/4885
US-20060287369-A1 Diarylmethyl and related compounds ADRB2, ADRB1, ADRA2B CYP2D6 698/4885HRH1 95/4885MEN1 3434/4885
US-20110015152-A1 DIARYLMETHYL AND RELATED COMPOUNDS ADRB2, ADRB1, ADRA2B CYP2D6 698/4885HRH1 95/4885MEN1 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback